schizophrenia

R&D

At the Sachs Neuroscience Forum just before the start of JPM 2026 in San Francisco, pharmaphorum spoke with Amit Etkin, CEO of Alto Neuroscience.

News

MapLight Therapeutics has made its debut on the Nasdaq, raising $251m for a lead drug that could be a rival to BMS' new schizophrenia drug Cobenfy.

News

Boehringer Ingelheim and Click Therapeutics have revealed the data from their pivotal trial of a digital therapeutic for schizophrenia.

News

Bristol Myers Squibb's price tag for schizophrenia drug Cobenfy in the UK is a manifestation of Trump's most favoured nation drug pricing policy.

News

After a promising start, IPOs all but fizzled out this year, but LB Pharma is hoping that won't stymy its chances of completing a Nasdaq listing.

News

Click and Boehringer Ingelheim make progress in software-enhanced drug treatment for schizophrenia with a positive phase 3 trial of their CT-155 app.